AlphAIalphai — Financial news for AI agents
Quiver QuantitativeMAY 63 min read$BTMD

Biote Corp. (BTMD) Releases Q1 2026 Earnings: Revenue Falls 8.3% While EPS Beats Estimates

Biote Corp. (BTMD) reported its Q1 2026 earnings, with revenue declining 8.3% year-over-year to $44.9 million, falling short of analyst estimates. Despite the revenue miss, diluted EPS of $0.06 surpassed the estimated $0.05. The company also showed tighter liquidity and reduced capital spending, with cash and cash equivalents down 87.2% year-over-year.

Original reporting
Quiver Quantitative · Quiver EarningsTracker
Published May 6, 2026, 9:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 6, 2026, 10:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Biote Corp. (BTMD) Releases Q1 2026 Earnings: Revenue Falls 8.3% While EPS Beats Estimates — source image
Source · Quiver Quantitative
Decision brief

The 30-second read

$BTMDBearishMed
01

Why it matters

The earnings report may lead to short-term volatility, especially if investors focus on revenue decline.

02

Market read

Moderate relevance for biotech investors; limited impact on broader markets.

03

What to watch

Potential upcoming catalysts such as product approvals or partnerships could offset current concerns.

Timing: short-term (next 1-2 weeks)

Background

Biote Corp. operates in the biotech sector, with recent earnings showing mixed results amid sector-wide volatility.

Company-level read

Ticker impact

$BTMDBearishMedium confidence
Context

The news pertains directly to Biote Corp. (BTMD), providing recent earnings data and financial performance indicators.

Expected impact

Potential short-term decline due to revenue miss and liquidity concerns, but EPS beat may provide some support.

Evidence & confidence

Revenue decline and liquidity reduction are negative signals; however, EPS beat suggests some operational resilience. Market reaction may be mixed.

Market effects

Sector

The life sciences sector may experience cautious trading due to earnings misses across similar companies.

Regional

Limited regional impact; company-specific news.

Global

Low; primarily relevant to biotech and healthcare investors.

Counterpoint

What could challenge this read

The EPS beat indicates operational strength; the revenue decline may be a temporary issue or market overreaction.

Key entities

  • Company
    Biote Corp.

    A biotech firm specializing in innovative therapies.

Read at source← All news

Related articles

AUG 7
$BTMDMed

biote Q2 Earnings Call Highlights

Biote (NASDAQ: BTMD) reported Q2 net loss of $7.4M ($0.23/share) versus prior-year net income of $3.9M, and adjusted EBITDA of $5.6M (12.6% margin). Gross margin fell to 65.4% from 71.6% due to higher-cost third-party pellets during a disruption and $600k recall-related costs. Biote cut its 2026 outlook to revenue above $175M and adjusted EBITDA above $25M.

yahoo.com6 min
AUG 5
$BTMDMed

biote Corp. (BTMD): Results of Operations and Financial Condition

biote Corp. (BTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Biote Reports Second Quarter 2026 Financial Results Continued progress in advancing strategic initiatives Updates full-year outlook Second Quarter 2026 Financial Highlights • Revenue of $44.2 million • Gross profit margin of 65.4% • Net loss of $(7.4) million and diluted loss per

SEC EDGAR 8-K6 min
AUG 28
$HONLow

What Honeywell International (HON)'s Automation Leadership Shake-Up Means For Shareholders

Honeywell International (HON) announced leadership changes in its automation portfolio, appointing Billal Hammoud as President and CEO of Process Technology and Juan Picon to lead Building Automation. The company projects $22.5 billion revenue and $3.2 billion earnings by 2029, implying a 16.1% yearly revenue decline and a $5.1 billion earnings decrease from current levels. Analysts have mixed views on the impact of the planned spin-offs and leadership changes on the company's valuation and futu

simplywall.st2 min
AUG 28
$NXEMed

Is BHP Group (BHP) the Missing Piece in NexGen Energy (NXE)’s $1 Billion Financing Plan?

NexGen Energy (NXE) is in talks with BHP Group (BHP) for a potential equity stake and financing for its Rook I uranium project. NexGen aims to raise $1 billion over nine months. BHP reported strong financials, with $33 billion in EBITDA and $9.8 billion in free cash flow. NexGen has no revenue but holds $970.25 million in cash. Investors should watch for a formal partnership between the two.

insidermonkey.com3 min